KISQALI
These highlights do not include all the information needed to use KISQALI safely and effectively. See full prescribing information for KISQALI. KISQALI (ribociclib) tablets, for oral use Initial U.S. Approval: 2017
aaeaef94-f3f5-4367-8ea2-b181d7be2da8
HUMAN PRESCRIPTION DRUG LABEL
Aug 24, 2023
Novartis Pharmaceuticals Corporation
DUNS: 002147023
Products 3
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
ribociclib
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (13)
ribociclib
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (13)
ribociclib
Product Details
FDA regulatory identification and product classification information